Familial Hypercholesterolemia
LIB Therapeutics Inc. focuses on cholesterol-lowering research for heterozygous familial hypercholesterolemia and homozygous familial hypercholesterolemia, with studies addressing persistent LDL cholesterol elevation in patients receiving background lipid-lowering therapy.
- HeFH
- HoFH
- LDL-C reduction
The sponsor’s clinical work in this area includes both adult and pediatric populations affected by inherited lipid disorders.
Cardiovascular Risk Reduction
Another key area of interest is cardiovascular disease and high cardiovascular risk, including patients with severe lipid abnormalities who remain vulnerable to major cardiovascular complications despite established treatment.
- Very-high cardiovascular risk
- High-risk lipid management
- Cholesterol control
Research in this domain centers on improving long-term lipid management in people with substantial cardiovascular burden.
Pediatric Lipid Disorders
LIB Therapeutics Inc. also studies familial hypercholesterolemia in children and adolescents, reflecting an interest in early intervention for inherited lipid disorders during developmental years.
- Children and adolescents
- Pediatric hypercholesterolemia
- Inherited cholesterol disorders
This area includes patients aged 6 to 17 years with ongoing need for effective cholesterol reduction.
Long-Term Lipid Therapy Evaluation
The sponsor’s trials also examine the ongoing safety, tolerability, and efficacy of investigational lipid-lowering treatment in patients continuing chronic management for familial hypercholesterolemia and related cardiovascular conditions.
- Long-term treatment assessment
- Chronic lipid management
- Subcutaneous therapy
These studies support continued attention to sustained cholesterol lowering in both inherited and cardiovascular risk settings.
